Promus Capital LLC purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 1,461 shares of the company's stock, valued at approximately $604,000. IDEXX Laboratories accounts for approximately 0.6% of Promus Capital LLC's holdings, making the stock its 28th biggest position.
Other institutional investors also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its position in IDEXX Laboratories by 15.0% during the third quarter. Farther Finance Advisors LLC now owns 805 shares of the company's stock valued at $407,000 after buying an additional 105 shares during the period. Chicago Partners Investment Group LLC increased its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after acquiring an additional 96 shares in the last quarter. Van ECK Associates Corp lifted its position in IDEXX Laboratories by 10.4% during the 3rd quarter. Van ECK Associates Corp now owns 25,133 shares of the company's stock valued at $12,698,000 after acquiring an additional 2,367 shares during the period. National Pension Service grew its holdings in IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after purchasing an additional 12,647 shares during the period. Finally, QRG Capital Management Inc. increased its stake in shares of IDEXX Laboratories by 4.8% during the third quarter. QRG Capital Management Inc. now owns 2,107 shares of the company's stock valued at $1,064,000 after purchasing an additional 96 shares in the last quarter. 87.84% of the stock is owned by institutional investors.
Insider Buying and Selling at IDEXX Laboratories
In other news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.
IDEXX Laboratories Stock Performance
Shares of IDXX stock traded up $1.09 on Friday, reaching $430.12. The stock had a trading volume of 654,250 shares, compared to its average volume of 542,991. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $562.25. The stock has a market cap of $34.98 billion, a P/E ratio of 40.31, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a 50 day simple moving average of $437.37 and a 200 day simple moving average of $449.41.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the company. Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.
Check Out Our Latest Report on IDXX
IDEXX Laboratories Company Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
